Evaluation of sensitivity to endocrine herapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031)

Authors

Vera J Suman, Mayo Clinic
Lili Du, The University of Texas MD Anderson Cancer Center
Tanya Hoskin, Mayo Clinic
Meenakshi Anurag, Baylor College of Medicine/Dan L. Duncan Comprehensive Cancer Center
Cynthia Ma, Washington University School of Medicine in St. Louis
Isabelle Bedrosian, The University of Texas MD Anderson Cancer Center
Kelly K Hunt, The University of Texas MD Anderson Cancer Center
Matthew J Ellis, Baylor College of Medicine/Dan L. Duncan Comprehensive Cancer Center
W Fraser Symmans, The University of Texas MD Anderson Cancer Center

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

8-2-2022

Volume

28

Issue

15

First Page

3287

Last Page

3295

Document Type

Open Access Publication

DOI

10.1158/1078-0432.CCR-22-0068

Rights and Permissions

Suman VJ, Du L, Hoskin T, Anurag M, Ma C, Bedrosian I, Hunt KK, Ellis MJ, Symmans WF. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res. 2022 Aug 2;28(15):3287-3295. doi: 10.1158/1078-0432 This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Recommended Citation

Suman, Vera J; Du, Lili; Hoskin, Tanya; Anurag, Meenakshi; Ma, Cynthia; Bedrosian, Isabelle; Hunt, Kelly K; Ellis, Matthew J; and Symmans, W Fraser, "Evaluation of sensitivity to endocrine herapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031)." Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 15. 3287 - 3295. (2022).
https://digitalcommons.wustl.edu/oa_4/104